(microsoft word - ok formul\341rio far410025 - prof. celso)
PROPOSTA DE PROGRAMA DE DISCLIPLINA NOME: FAR410025 - Tópicos Especiais - Nanotecnologia como ferramenta terapêutica para o
tratamento do câncer SEMESTRE: 2012/2 ÁREA DE CONCENTRAÇÃO:
( ) Fármacos-Medicamentos CRÉDITOS TEÓRICOS: 01 NÚMERO DE VAGAS (Regular e Especial): 15 CRÉDITOS PRÁTICOS: 00 LOCAL: Quartas: sala 02/Bloco H e Sextas: Sala 005/ACL DOCENTES: Celso Spada
Iara Fabricia Kretzer (Estágio Pós-doutoral) EMENTA: A pesquisa na área da nanotecnologia teve uma verdadeira explosão nos últimos anos,
deflagrada por grandes investimentos em todo o mundo, provenientes de fundos de pesquisa e
também empresariais. Desta forma, a nanotecnologia pode ser considerada como um dos
campos de pesquisa mais promissores em Ciência e está presente em formulações
farmacêuticas, processos químicos ou componentes eletrônicos manipulados dentro da escala
A disciplina se propõe a discutir a importância do estudo e conhecimento de características das
células tumorais que podem ser empregadas no desenvolvimento de ferramentas de diagnóstico,
biomarcadores, e estratégias terapêuticas para o tratamento do câncer, com ênfase neste último,
com o uso da nanotecnologia para o direcionamento de fármacos para o tecido tumoral.
CRONOGRAMA (datas, dia da semana, horário):
22/08 – Quarta: Sala 02 / Bloco H / CCS
24/08 – Sexta: Sala 005 / ACL / Bloco J / CCS
29/08 – Quarta: Sala 02 / Bloco H / CCS
31/08 – Sexta: Sala 005 / ACL / Bloco J / CCS
05/09 – Quarta: Sala 02 / Bloco H / CCS
12/09 – Quarta: Sala 02 / Bloco H / CCS
14/09 – Sexta: Sala 005 / ACL / Bloco J / CCS
19/09 – Quarta: Sala 02 / Bloco H / CCS
CONTEÚDO PROGRAMÁTICO: Módulo 1: Fisiopatologia das neoplasias e características dos tumores que podem ser utilizadas como alvo terapêutico. Quimioterapia convencional, efeitos adversos e estratégias para o tratamento do câncer. Módulo 2: Emprego da nanotecnologia no diagnóstico e tratamento do câncer, terapia-alvo. Seminários. Módulo 3: Modelos de avaliação de atividade de fármacos e terapia-alvo no tratamento do câncer e outras doenças degenerativas. Seminários. AVALIAÇÃO:
Apresentação oral de artigos científicos na forma de seminários e participação em discussão sobre os
Bibliografia: ARAC - ANIMAL RESEARCH ADVISORY COMMITTEE. Guidelines for Survival Bleeding of Mice and Rats. Bethesda, MD: National Institute of Health, 2010.
AZEVEDO, C.H.; CARVALHO, J.P.; VALDUGA, C.J.; MARANHAO, R.C. Plasma kinetics and uptake by the tumor of
a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol Oncol., v.97, p.178-182, 2005. BULGARELLI, A.; MARTINS DIAS, A.A.; CARAMELLI, B.; MARANHÃO, R.C. Treatment with methotrexate inhibits
atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol, v.59(4), p. 308-314, 2012. DE JONG, W.H.; BORM, P.J.A. Drug delivery and nanoparticles: Applications and Hazards. Int. Journal Nanomedicine, v. 3(2), p. 133-149, 2008. DEVITA, V.T.; HELLMAN, S.; ROSENBERG, S.A. Cancer: Principles & Practice of Oncology. 8th Ed. Philadelphia: Lippincott Wil iams & Wilkins, 2008.
DIAS, M.L.; CARVALHO, J.P.; RODRIGUES, D.G.; GRAZIANI, S.R.; MARANHÃO, R.C. Pharmacokinetics and tumor
uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with
gynecologic cancers. Cancer Chemother Pharmacol., v.59(1), p.105-111, 2007. GRAZIANI, S.R.; IGREJA, F.A.F.; HEGG, R.; MENEGHETTI, C.; BRANDIZZI, L.I.; BARBOSA, R.; AMANCIO, F.R.;
PINOTTI, J.A.; MARANHÃO, R.C. Uptake of a cholesterol rich emulsion by breast cancer. Ginecologic Oncology., v.85, p.493-497, 2002.
FERRARI, M. CANCER NANOTECHNOLOGY: OPPORTUNITIES AND CHALLENGES. Nature Reviews Cancer, v.5, p. 161-171, 2005.
HERREROS-VILLANUEVA, M.; HIJONA, E.; COSME, A.; BUJANDA, L. Mouse models of pancreatic cancer. World J Gastroenterol., v.(12), p.1286-1294, 2012.
HWANG, H.; KIM, I.; KWON, I.C.; KIM, Y. Tumor targetability and antitumor effect of docetaxel-loaded
hydrophobical y modified glycol chitosan nanoparticles. Journal of Controlled Release, v.128, p.23–31, 2008. KINGSLEY, J.D.; DOU, H.; MOREHEAD, J.; RABINOW, B.; GENDELMAN, H.E.; DESTACHE, C.J. Nanotechnology:
A Focus on Nanoparticles as a Drug Delivery System. J Neuroimmune Pharmacol, v.1, p.340–350, 2006.
KOUDELKA, S.; TURÁNEK-KNÖTIGOVÁ, P.; MASEK, J.; KORVASOVÁ, Z.; SKRABALOVÁ, M.; PLOCKOVÁ, J.;
BARTHELDYOVÁ, E.; TURÁNEK, J. Liposomes with high encapsulation capacity for paclitaxel: Preparation,
characterisation and in vivo anticancer effect. J Pharm Sci., v.99(5), p.2309-2319, 2010. LO PRETE, A.C.; MARIA, A.D.; RODRIGUES, D.G.; VALDUGA, C.J.; IBAÑEZ, O.C.M.; MARANHÃO, R.C.
Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol rich-microemulsion. J.Pharm.Pharmacol., v.58(6), p.801-808, 2006. LOURENÇO-FILHO, D.D.; MARANHÃO, R.C.; MÉNDEZ-CONTRERAS, C.A.; TAVARES, E.R.; FREITAS, F.R.;
STOLF, N.A. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in
a rabbit graft model. J Thorac Cardiovasc Surg., v.141(6), p.1522-1528, 2011.
MAMOT, C.; DRUMMOND, D.C.; HONG, K; KIRPOTIN, D.B.; PARK, J.W. Liposome-based approaches to overcome
anticancer drug resistance. Drug Resist Updat., v. 6(5), p.271-279, 2003. MARANHÃO, R.C.; GRAZIANI, S.R.; YAMAGUCHI, N.; MELO, R.F.; LATRILHA, M.C.; RODRIGUES, D.G; COUTO,
R.D.; SCHREIER, S.; BUZAID, A.C. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary
studies in cancer patients. Cancer Chemother. Pharmacol., v.49(6), p.487-498, 2002. MENDES, S.; GRAZIANI, S.R.; VITÓRIO, T.S.; PADOVEZE, A.F.; HEGG, R.; BYDLOWSKI, S.P.; MARANHÃO, R.C.
Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for
neoadjuvant chemotherapy. Gynecol Oncol., v.112(2), p.400-404, 2009.
MOURA JA, VALDUGA CJ, TAVARES ER, KRETZER IF, MARIA DA, MARANHAO RC. Novel formulation of a
methotrexate derivative with a lipid nanoemulsion. International Journal of Nanomedicine, v.6, p.2285-2295, 2011
PEPPAS, L.B.; BLANCHETTE J.O. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews, v.56, p.1649– 1659, 2006.
PLOWMAN, J.; DYKER, D.J.; HOLLINGSHEAD, M.; SIMPSON-HERREN; ALLEY, M.C. Human tumor xenograft models in NCl development, in Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval. Totowa,New Jersey: (B.A. Teicher ed.) Humana Press, 1997. p.101-125. REDDY, R.H. Drug delivery to tumours: recent strategies. Journal of Pharmacy and Pharmacology, v.57, p.1231–
RODRIGUES, D.G., MARIA, D.A., FERNANDES, D.C., VALDUGA, C.J., COUTO, R.D., IBAÑEZ, O.C. M.,
MARANHÃO, R.C., Improvement of Paclitaxel Therapeutic Index by Derivatization and Association to a Cholesterol-
Rich Microemulsion: In Vitro and In Vivo Studies. Cancer Chemother. Pharmacol., v.55, p.565, 2005.
SENGUPTA, S.; TYAGI, P.; CHANDRA, S; KOCHUPILLAI, V.; GUPTA, S.K. Encapsulation in cationic liposomes
enhances antimour efficacy and reduces the toxicity of etoposide, a topoisomerase II inhibitor. Pharmacology., v.62(3), p.163-171, 2001.
TAVARES, E.R.; FREITAS, F.R.; DIAMENT, J.; MARANHÃO, R.C. Reduction of atherosclerotic lesions in rabbits
treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomedicine, v.6, p.2297-2304, 2011. VASSILEVA, V.; GRANT, J.; SOUZA, R.; ALLEN, C.; PIQUETTE, M.M. Novel biocompatible intraperitoneal drug
delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft
model. Cancer Chemother Pharmacol., v.60(6), p.907-914, 2007. ZHAO, X.; LI, H.; LEE, R.J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv., v.5(3, p.309-319, 2008.
LC-MS in environmental trace analyses – a challenge for reliable data monitoring Sebastian Zuehlke Introduction The fate of pharmaceutical residues, personal care products and endocrine disrupting compounds has be en recognized as an emerging issue in environmental research [Heberer, 2002; Kümmerer, 2001; Daughton & Ternes 1999]. Thus, reliable data on occurrence and fate of
MALATTIA PARODONTALE dall’aggressione batteria alla risposta dell’ospite di Andrea Pilloni Professore Associato di Parodontologia presso l’Università la Sapienza di Roma (supplemento alla Rivista Doctor OS del settembre 2007) EPIDEMIOLOGIA E FATTORI DI RISCHIO Prevalenza Il 90% della popolazione soffre di qualche forma di malattia delle gengive, con il 54%degli adulti che presentano tasc
PROPOSTA DE PROGRAMA DE DISCLIPLINA 
Módulo 1: Fisiopatologia das neoplasias e características dos tumores que podem ser utilizadas 
HWANG, H.; KIM, I.; KWON, I.C.; KIM, Y. Tumor targetability and antitumor effect of docetaxel-loaded
hydrophobical y modified glycol chitosan nanoparticles. Journal of Controlled Release, v.128, p.23–31, 2008. KINGSLEY, J.D.; DOU, H.; MOREHEAD, J.; RABINOW, B.; GENDELMAN, H.E.; DESTACHE, C.J. Nanotechnology:
A Focus on Nanoparticles as a Drug Delivery System. J Neuroimmune Pharmacol, v.1, p.340–350, 2006.
KOUDELKA, S.; TURÁNEK-KNÖTIGOVÁ, P.; MASEK, J.; KORVASOVÁ, Z.; SKRABALOVÁ, M.; PLOCKOVÁ, J.;
BARTHELDYOVÁ, E.; TURÁNEK, J. Liposomes with high encapsulation capacity for paclitaxel: Preparation,
characterisation and in vivo anticancer effect. J Pharm Sci., v.99(5), p.2309-2319, 2010. LO PRETE, A.C.; MARIA, A.D.; RODRIGUES, D.G.; VALDUGA, C.J.; IBAÑEZ, O.C.M.; MARANHÃO, R.C.
Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol rich-microemulsion. J.Pharm.Pharmacol., v.58(6), p.801-808, 2006. LOURENÇO-FILHO, D.D.; MARANHÃO, R.C.; MÉNDEZ-CONTRERAS, C.A.; TAVARES, E.R.; FREITAS, F.R.;
STOLF, N.A. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in
a rabbit graft model. J Thorac Cardiovasc Surg., v.141(6), p.1522-1528, 2011.
MAMOT, C.; DRUMMOND, D.C.; HONG, K; KIRPOTIN, D.B.; PARK, J.W. Liposome-based approaches to overcome
anticancer drug resistance. Drug Resist Updat., v. 6(5), p.271-279, 2003. MARANHÃO, R.C.; GRAZIANI, S.R.; YAMAGUCHI, N.; MELO, R.F.; LATRILHA, M.C.; RODRIGUES, D.G; COUTO,
R.D.; SCHREIER, S.; BUZAID, A.C. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary
studies in cancer patients. Cancer Chemother. Pharmacol., v.49(6), p.487-498, 2002. MENDES, S.; GRAZIANI, S.R.; VITÓRIO, T.S.; PADOVEZE, A.F.; HEGG, R.; BYDLOWSKI, S.P.; MARANHÃO, R.C.
Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: a new strategy for
neoadjuvant chemotherapy. Gynecol Oncol., v.112(2), p.400-404, 2009.
MOURA JA, VALDUGA CJ, TAVARES ER, KRETZER IF, MARIA DA, MARANHAO RC. Novel formulation of a
methotrexate derivative with a lipid nanoemulsion. International Journal of Nanomedicine, v.6, p.2285-2295, 2011
PEPPAS, L.B.; BLANCHETTE J.O. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews, v.56, p.1649– 1659, 2006.
TAVARES, E.R.; FREITAS, F.R.; DIAMENT, J.; MARANHÃO, R.C. Reduction of atherosclerotic lesions in rabbits
treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomedicine, v.6, p.2297-2304, 2011. VASSILEVA, V.; GRANT, J.; SOUZA, R.; ALLEN, C.; PIQUETTE, M.M. Novel biocompatible intraperitoneal drug
delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft
model. Cancer Chemother Pharmacol., v.60(6), p.907-914, 2007. ZHAO, X.; LI, H.; LEE, R.J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv., v.5(3, p.309-319, 2008.